HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Flips Script On Infomercial Couple Making Bogus Supplement Claims

This article was originally published in The Rose Sheet

Executive Summary

A settlement announced Oct. 4, the same day it filed a complaint against Supple LLC and its principals, marks the agency's second notable win in litigation, after its prolonged battle with Kevin Trudeau, against infomercial marketers making unsubstantiated claims for supplements.

You may also be interested in...



Trudeau's 'Fanciful Explanations' Fail In Appealing Contempt Conviction

An appeals court upholds former diet pitch man Kevin Trudeau's 10-year sentence for violating a consent decree on fraudulent health claims he made in infomercials. Trudeau said he misinterpreted the decree as allowing statements of opinion in his infomercials because they are protected by the First Amendment.

Supplements’ Direct Response Marketing Success Sets Off FTC Alarm

Dietary supplement firms could face more aggressive enforcement from the Federal Trade Commission as they take advantage of increased direct response marketing opportunities created by the recession

US Health And Wellness People News: CHPA, Bayer, Viatris, Qnovia, Powerade

Sanofi consumer health scientific affairs lead moves to CHPA; change in Bayer’s US consumer health marketing helm; Viatris CCO moves from same post at Moderna; Qnovia expands scientific advisory board; and Powerade powers Girls Inc. scholarships, programs.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel